• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Imago BioSciences Inc. (Amendment)

    4/1/22 5:18:59 PM ET
    $IMGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGO alert in real time by email
    SC 13D/A 1 d277368dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Imago BioSciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    45250K107

    (CUSIP Number)

    Robert Liptak

    Clarus Ventures, LLC

    101 Main Street, Suite 1210

    Cambridge, MA 02142

    (617) 949-2200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    March 30, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Clarus Lifesciences III, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,375,037

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,375,037

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,375,037

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.0%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    2


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Clarus Ventures III GP, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,375,037

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,375,037

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,375,037

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.0%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    3


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Clarus III L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,375,037

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,375,037

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,375,037

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.0%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    4


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Holdings II L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Quebec, Canada

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,436,732

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,436,732

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,436,732

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.2%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    5


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Holdings I/II GP L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,436,732

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,436,732

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,436,732

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.2%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    6


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,436,732

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,436,732

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,436,732

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.2%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

    7


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Blackstone Group Management L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,436,732

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,436,732

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,436,732

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.2%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

     

    8


    CUSIP No. 45250K107

     

      1    

      NAMES OF REPORTING PERSONS

     

      Stephen A. Schwarzman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,436,732

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,436,732

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,436,732

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      7.2%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

     

    9


    This Amendment No. 1 (“Amendment No. 1”) to the statement on Schedule 13D amends and supplements the initial statement on Schedule 13D filed on July 30, 2021 (as amended, the “Schedule 13D”) relating to the common stock, par value $0.0001 per share (the “Common Stock”) of Imago BioSciences, Inc., a Delaware corporation (the “Issuer”).

    Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D.

     

    Item 2.

    Identity and Background

    Item 2 of the Schedule 13D is hereby amended by incorporating herein by reference the information set forth on the updated Schedule I attached hereto.

     

    Item 5.

    Interest in Securities of the Issuer

    Item 5(a) – (c) of the Schedule 13D is hereby amended and restated as follows:

    (a) and (b) Calculations of the percentage of the shares of Common Stock beneficially owned is based on 33,706,657 shares of Common Stock outstanding as of March 11, 2022, based on information set forth in the Annual Report on Form 10-K filed by the Issuer on March 24, 2022.

    The aggregate number and percentage of the Common Stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of Schedule 13D and are incorporated herein by reference.

    As of the date hereof, the Fund directly holds 2,375,037 shares of Common Stock and an investment fund affiliated with the Fund beneficially owns 61,695 shares of Common Stock, received in the Fund Distribution described in Item 5(c) below.

    Clarus GP is the general partner of the Fund. Blackstone Clarus III L.L.C. is the general partner of Clarus GP. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is Blackstone Inc. The sole holder of the Series II preferred stock of Blackstone Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone’s senior managing directors and controlled by its founder, Stephen A. Schwarzman.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person is the beneficial owner of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such shares of Common Stock.

    (c) On March 30, 2022, the Fund distributed 1,000,000 shares of Common Stock to its partners, including Clarus GP (the “Fund Distribution”) and an investment fund affiliated with the Fund, which received 61,695 of the shares of Common Stock. Clarus GP then distributed the 237,051 shares it received in the Fund Distribution to its partners. Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

     

    10


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 1, 2022

     

    CLARUS LIFESCIENCES III, L.P.
    By:   Clarus Ventures III GP, L.P., its general partner
    By:   Blackstone Clarus III, L.L.C., its general partner
    By:  

    /s/ Omar Rehman

    Name: Omar Rehman
    Title: Chief Compliance Officer and Secretary
    CLARUS VENTURES III GP, L.P.
    By:   Blackstone Clarus III, L.L.C., its general partner
    By:  

    /s/ Omar Rehman

    Name: Omar Rehman
    Title: Chief Compliance Officer and Secretary
    BLACKSTONE CLARUS III L.L.C.
    By:  

    /s/ Omar Rehman

    Name: Omar Rehman
    Title: Chief Compliance Officer and Secretary


    BLACKSTONE HOLDINGS II L.P.
    By:   Blackstone Holdings I/II GP L.L.C., its general partner
    By:  

    /s/ Tabea Hsi

    Name: Tabea Hsi
    Title: Senior Managing Director
    BLACKSTONE HOLDINGS I/II GP L.L.C.
    By:  

    /s/ Tabea Hsi

    Name: Tabea Hsi
    Title: Senior Managing Director
    BLACKSTONE INC.
    By:  

    /s/ Tabea Hsi

    Name:   Tabea Hsi
    Title:   Senior Managing Director
    BLACKSTONE GROUP MANAGEMENT L.L.C.
    By:  

    /s/ Tabea Hsi

    Name:   Tabea Hsi
    Title:   Senior Managing Director

    /s/ Stephen A. Schwarzman

    Stephen A. Schwarzman

    [Imago BioSciences, Inc. – Schedule 13D]


    SCHEDULE I

    Executive Officers and Directors of Blackstone Inc.

    The name and principal occupation of each director and executive officer of Blackstone Inc. are set forth below. The address for each person listed below is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154. All executive officers and directors listed are United States citizens other than The Right Honourable Brian Mulroney, who is a citizen of Canada, and Sir John Antony Hood, who is a citizen of New Zealand.

    OFFICERS:

     

    Name   

    Present Principal Occupation or Employment

    Stephen A. Schwarzman    Founder, Chairman and Chief Executive Officer of Blackstone Inc.
    Jonathan D. Gray    President, Chief Operating Officer of Blackstone Inc.
    Michael S. Chae    Chief Financial Officer of Blackstone Inc.
    John G. Finley    Chief Legal Officer of Blackstone Inc.

    DIRECTORS:

     

    Name   

    Present Principal Occupation or Employment

    Stephen A. Schwarzman    Founder, Chairman and Chief Executive Officer of Blackstone Inc.
    Jonathan D. Gray    President, Chief Operating Officer of Blackstone Inc.
    Kelly A. Ayotte    Former United States Senator from New Hampshire
    Joseph P. Baratta    Global Head of Private Equity at Blackstone Inc.
    James W. Breyer    Founder and Chief Executive Officer of Breyer Capital
    Reginald J. Brown    Partner for the law firm, Kirkland & Ellis
    Sir John Antony Hood    Former President and Chief Executive Officer of the Robertson Foundation and Former Chair of the Rhodes Trust
    Rochelle B. Lazarus    Chairman Emeritus & Former Chief Executive Officer, Ogilvy & Mather Worldwide
    Jay O. Light    Dean Emeritus, Harvard Business School
    The Right Honourable Brian Mulroney    Senior Partner for the Montreal law firm, Norton Rose Fulbright Canada LLP
    William G. Parrett    Retired CEO of Deloitte Touche Tohmatsu and retired Senior Partner of Deloitte (USA)
    Ruth Porat    Chief Financial Officer of Alphabet Inc. and Google Inc.
    Get the next $IMGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMGO

    DatePrice TargetRatingAnalyst
    10/28/2022$25.00Outperform
    Wedbush
    2/14/2022$37.00Buy
    HC Wainwright & Co.
    8/10/2021$30.00Buy
    Jefferies
    8/10/2021$35.00Buy
    Guggenheim
    8/10/2021Outperform
    Cowen
    8/10/2021$31.00Buy
    Stifel
    More analyst ratings

    $IMGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Imago BioSciences with a new price target

      Wedbush initiated coverage of Imago BioSciences with a rating of Outperform and set a new price target of $25.00

      10/28/22 7:20:34 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Imago BioSciences with a new price target

      HC Wainwright & Co. initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $37.00

      2/14/22 6:06:11 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Imago BioSciences with a new price target

      Jefferies initiated coverage of Imago BioSciences with a rating of Buy and set a new price target of $30.00

      8/10/21 8:46:38 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Imago BioSciences Inc.

      15-12G - Imago BioSciences, Inc. (0001623715) (Filer)

      1/23/23 7:25:29 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Imago BioSciences Inc.

      EFFECT - Imago BioSciences, Inc. (0001623715) (Filer)

      1/17/23 12:15:09 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Imago BioSciences Inc.

      25-NSE - Imago BioSciences, Inc. (0001623715) (Subject)

      1/11/23 10:41:33 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Keating Laurie

      4 - Imago BioSciences, Inc. (0001623715) (Issuer)

      1/11/23 4:23:43 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Tapper Amy E. closing all direct ownership in the company

      4 - Imago BioSciences, Inc. (0001623715) (Issuer)

      1/11/23 4:19:43 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kariuki Enoch

      4 - Imago BioSciences, Inc. (0001623715) (Issuer)

      1/11/23 4:19:47 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer

      SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Michael Arenberg to Chief Operating and Business Officer. Mr. Arenberg is a distinguished biopharmaceutical executive who will be charged with leading strategic operations, investor relations, commercial development and business development of Imago. "I welcome Mike to Imago with great enthusiasm at this important stage of company development," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSc

      3/23/22 4:05:00 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Appoints Laurie Keating as Chair of Board of Directors

      BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Directors. "We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focu

      1/19/22 8:00:00 AM ET
      $IMGO
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imago BioSciences Appoints Laurie Keating to Board of Directors

      ​Imago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021. Keating is a seasoned executive, with nearly two decades of her 40-year career in diverse roles within the biopharmaceutical industry. "I am pleased to welcome to Laurie to Imago's Board of Directors as the company continues to grow, following our successful IPO in July," said Hugh Young Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. "Laurie brings extensive experience to our Board and we look forward

      11/18/21 4:05:00 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (NASDAQ:IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All

      1/11/23 6:45:00 AM ET
      $IMGO
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

      REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatme

      12/20/22 4:05:00 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

      - 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with baseline loss of heterozygosity (LOH) and follow-up samples showed a reduction in homozygous mutant granulocytes and mutant allele frequencies – -Aligned with FDA on strategy for bomedemstat pivotal

      12/12/22 11:30:00 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      2/14/23 8:26:45 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      2/1/23 5:16:35 PM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Imago BioSciences Inc. (Amendment)

      SC 13G/A - Imago BioSciences, Inc. (0001623715) (Subject)

      1/26/23 8:52:16 AM ET
      $IMGO
      Biotechnology: Pharmaceutical Preparations
      Health Care